Hisataka Kobayashi

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies
    Yoshinori Koyama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1B40, Bethesda, MD, 20892 1088, USA
    Neoplasia 9:1021-9. 2007
  2. ncbi Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy
    Makoto Mitsunaga
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC1088, Bethesda, MD, 20892 1088, USA
    BMC Cancer 12:345. 2012
  3. ncbi Recent advances in optical cancer imaging of EGF receptors
    G Kramer-Marek
    Molecular Imaging Program, National Cancer Institute NIH, Bldg 10, Room B3B69, MSC 1088, Bethesda, Maryland 20892 1088, USA
    Curr Med Chem 19:4759-66. 2012
  4. ncbi Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1374, USA
    Magn Reson Med 50:758-66. 2003
  5. ncbi Micro-MRI methods to detect renal cysts in mice
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Kidney Int 65:1511-6. 2004
  6. ncbi Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1374, USA
    J Natl Cancer Inst 96:703-8. 2004
  7. ncbi Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Magn Reson Imaging 20:512-8. 2004
  8. ncbi Dendrimer-based nanosized MRI contrast agents
    Hisataka Kobayashi
    Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bldg 10, Room B3B69, MCS 1002, 10 Center Dr, Bethesda, MD 20892 1002, USA
    Curr Pharm Biotechnol 5:539-49. 2004
  9. ncbi Two-color in vivo dynamic contrast-enhanced pharmacokinetic imaging
    Yukihiro Hama
    National Cancer Institute NIH, Center for Cancer Research, Molecular Imaging Program, Bethesda, Maryland 20892 1088, USA
    J Biomed Opt 12:034016. 2007
  10. ncbi Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents
    Hisataka Kobayashi
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH Bldg 10, Room 1B40, MSC 1088, 10 Center Drive, Bethesda, MD 20892 1088, USA
    Nanomedicine (Lond) 4:411-9. 2009

Collaborators

Detail Information

Publications96

  1. ncbi In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies
    Yoshinori Koyama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1B40, Bethesda, MD, 20892 1088, USA
    Neoplasia 9:1021-9. 2007
    ..Multiple filter sets increase the signal-to-noise ratio by substantially reducing the background signal, and may allow more optical dyes to be resolved within the narrow limits of the near-infrared spectrum...
  2. ncbi Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy
    Makoto Mitsunaga
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room B3B69, MSC1088, Bethesda, MD, 20892 1088, USA
    BMC Cancer 12:345. 2012
    ..abstract:..
  3. ncbi Recent advances in optical cancer imaging of EGF receptors
    G Kramer-Marek
    Molecular Imaging Program, National Cancer Institute NIH, Bldg 10, Room B3B69, MSC 1088, Bethesda, Maryland 20892 1088, USA
    Curr Med Chem 19:4759-66. 2012
    ..Such agents provide the opportunity for earlier diagnosis, improved tumor characterization, and the ability to measure and monitor tumor responsiveness to anti-EGF receptor treatment strategies...
  4. ncbi Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1374, USA
    Magn Reson Med 50:758-66. 2003
    ..In conclusion, DAB-G5 and PAMAM-G4 can be used to identify lymph nodes and lymphatic vessels, respectively. Their rapid excretion makes these compounds potentially attractive for human use...
  5. ncbi Micro-MRI methods to detect renal cysts in mice
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Kidney Int 65:1511-6. 2004
    ....
  6. ncbi Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1374, USA
    J Natl Cancer Inst 96:703-8. 2004
    ..Improving current magnetic resonance (MR) imaging methods using a newly synthesized nano-size paramagnetic molecule, G6, as a contrast agent, provides an attractive means toward attaining this goal...
  7. ncbi Polyamine dendrimer-based MRI contrast agents for functional kidney imaging to diagnose acute renal failure
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Magn Reson Imaging 20:512-8. 2004
    ..We synthesized and compared smaller polyamine dendrimer-based MRI contrast agents (<60 kD) that, unlike Gd-[DTPA], transiently accumulate in renal tubules and can be used to visualize renal structural and functional damage...
  8. ncbi Dendrimer-based nanosized MRI contrast agents
    Hisataka Kobayashi
    Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bldg 10, Room B3B69, MCS 1002, 10 Center Dr, Bethesda, MD 20892 1002, USA
    Curr Pharm Biotechnol 5:539-49. 2004
    ....
  9. ncbi Two-color in vivo dynamic contrast-enhanced pharmacokinetic imaging
    Yukihiro Hama
    National Cancer Institute NIH, Center for Cancer Research, Molecular Imaging Program, Bethesda, Maryland 20892 1088, USA
    J Biomed Opt 12:034016. 2007
    ..This imaging technique can be applied to a wide variety of optically labeled proteins in order to simultaneously track their biodistribution...
  10. ncbi Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents
    Hisataka Kobayashi
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH Bldg 10, Room 1B40, MSC 1088, 10 Center Drive, Bethesda, MD 20892 1088, USA
    Nanomedicine (Lond) 4:411-9. 2009
    ..Only one of these approaches is typically employed during an imaging examination. Here, we demonstrate the combined use of both approaches...
  11. ncbi Nano-sized MRI contrast agents with dendrimer cores
    Hisataka Kobayashi
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1B40, 10 Center Drive, Bethesda, MD 20892 1088, USA
    Adv Drug Deliv Rev 57:2271-86. 2005
    ....
  12. ncbi Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging
    Hisataka Kobayashi
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1B40, MSC1088, 10 Center Drive, Bethesda, MD 20892 1088, USA
    J Control Release 111:343-51. 2006
    ..Thus, when injected interstitially, the PAMAM-G6 Gd dendrimer not only provides excellent opacification of sentinel lymph nodes, but also provides the potential for targeted therapy of sentinel lymph nodes...
  13. ncbi Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging
    Hisataka Kobayashi
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1088, USA
    ACS Nano 1:258-64. 2007
    ....
  14. ncbi Simultaneous multicolor imaging of five different lymphatic basins using quantum dots
    Hisataka Kobayashi
    Molecular Imaging Program and Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1088, USA
    Nano Lett 7:1711-6. 2007
    ..This allows noninvasive and simultaneous visualization of five separate lymphatic flows draining and may have implications for predicting the route of cancer metastasis into the lymph nodes...
  15. ncbi Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Bioconjug Chem 14:1044-7. 2003
    ..Moreover, it permits the repeated injection of the contrast agent and the "avidin switch" during a single MR experiment...
  16. ncbi Dendrimer-based macromolecular MRI contrast agents: characteristics and application
    Hisataka Kobayashi
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4N109, 10 Center Drive, Bethesda, MD 20892 1374, USA
    Mol Imaging 2:1-10. 2003
    ....
  17. ncbi Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals
    Hisataka Kobayashi
    Molecular Imaging Program, National Cancer Institute NIH, Bldg 10, Room B3B69, MSC 1088, 10 Center Dr Bethesda, Maryland 20892 1088, USA
    Chem Soc Rev 40:4626-48. 2011
    ....
  18. ncbi Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation
    Hisataka Kobayashi
    Metabolism Branch, Radiation Biology Branch, and Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1002, USA
    Clin Cancer Res 10:7712-20. 2004
    ..Such information might be applied to optimize the efficacy of subsequent or concurrent therapies including radiolabeled antibodies or other anticancer agents in combination with external beam therapies...
  19. ncbi Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications
    Hisataka Kobayashi
    National Institutes of Health, Bethesda, Maryland 20892 1088, USA
    Acc Chem Res 44:83-90. 2011
    ....
  20. ncbi Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 63:271-6. 2003
    ....
  21. ncbi Multiplexed imaging in cancer diagnosis: applications and future advances
    Hisataka Kobayashi
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1088, USA
    Lancet Oncol 11:589-95. 2010
    ..In this review, we provide a broad overview of current and emerging multiplexed, imaging technologies...
  22. ncbi Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Bioconjug Chem 14:388-94. 2003
    ..Since PAMAM-G2, DAB-G3, and DAB-G2 dendrimer-based contrast agents showed relatively rapid excretion, these three conjugates might be acceptable for use in further clinical applications...
  23. ncbi Determination of optimal rhodamine fluorophore for in vivo optical imaging
    Michelle R Longmire
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1088, USA
    Bioconjug Chem 19:1735-42. 2008
    ..Herein, we demonstrate that the rhodamine-fluorophore, TAMRA, is the most robust of the 4 common rhodamine fluorophores for in vivo optical imaging of ovarian cancer metastases to the peritoneum...
  24. ncbi A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a "smart" fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1088, USA
    Clin Cancer Res 13:6335-43. 2007
    ..As a nonimmunogenic alternative of avidin, galactosamine-conjugated serum albumin (GmSA) targets the D-galactose receptor with higher binding affinity and has more conjugation sites available for rhodamineX than avidin...
  25. ncbi A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1088, USA
    Cancer Res 67:2791-9. 2007
    ....
  26. ncbi Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases
    Mikako Ogawa
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892 1088, USA
    Mol Pharm 6:386-95. 2009
    ..Thus, these activatable probes, based on the fluorophore-quencher system, hold promise clinically for "see and treat" strategies of cancer management...
  27. ncbi D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green
    Yukihiro Hama
    National Institutes of Health, National Cancer Institute, Center for Cancer Research, Molecular Imaging Program, Bethesda, Maryland 20892 1088, USA
    J Biomed Opt 12:051501. 2007
    ..These results indicate that GmSA-RhodG is not only a clinically feasible alternative but more efficient targeting reagent for D-galactose receptors than avidin-RhodG...
  28. ncbi Two-color lymphatic mapping using Ig-conjugated near infrared optical probes
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1088, USA
    J Invest Dermatol 127:2351-6. 2007
    ..This noninvasive and biocompatible multicolor method of optical lymphangiography may elucidate the complex human lymphatic system and reduce the risk of lymphedema after surgery for melanoma and other cancers...
  29. ncbi A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice
    Yoshinori Koyama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1088, USA
    J Magn Reson Imaging 25:866-71. 2007
    ..To preoperatively and intraoperatively localize the sentinel lymph node (SLN), a single hybrid probe for MR and near infrared (NIR) optical imaging was synthesized and tested...
  30. ncbi In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies
    Tristan Barrett
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Cancer Res 13:6639-48. 2007
    ..Here, we use a "cocktail" of optically labeled monoclonal antibodies directed against EGFR-1 (HER1) and EGFR-2 (HER2) to distinguish tumors by their cell surface expression profiles...
  31. ncbi Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu
    Yoshinori Koyama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1088, USA
    Clin Cancer Res 13:2936-45. 2007
    ....
  32. ncbi Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging
    Heng Xu
    Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892 1088, USA
    Bioconjug Chem 18:1474-82. 2007
    ..Thus, the avidin-biotin-dendrimer complex may be used as a tumor-targeted probe for dual-modality magnetic resonance and fluorescence imaging...
  33. ncbi Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer
    Michelle Longmire
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer Sci 100:1099-104. 2009
    ..We demonstrate that real-time in vivo multicolor imaging is feasible and that fluorescence characteristics can then serve to guide the surgical removal of disease...
  34. ncbi A comparison of the emission efficiency of four common green fluorescence dyes after internalization into cancer cells
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1088, USA
    Bioconjug Chem 17:1426-31. 2006
    ..This information could have implications for the design of tumor-targeted fluorescent probes that rely on cellular internalization for cancer detection...
  35. ncbi Two-step synthesis of galactosylated human serum albumin as a targeted optical imaging agent for peritoneal carcinomatosis
    Celeste Aida S Regino
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892 1088, USA
    J Med Chem 53:1579-86. 2010
    ....
  36. ncbi High sensitivity detection of cancer in vivo using a dual-controlled activation fluorescent imaging probe based on H-dimer formation and pH activation
    Mikako Ogawa
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1088, USA
    Mol Biosyst 6:888-93. 2010
    ..Thus, we demonstrate that a dual-controlled activatable optical probe based on the combination of H-dimer formation and pH activation can achieve high TBR at early time points during in vivo molecular imaging...
  37. ncbi Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle
    Hisataka Kobayashi
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1088, USA
    Neoplasia 7:984-91. 2005
    ....
  38. ncbi Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity
    Raya Mandler
    Metabolism Branch, Center for Cancer Research, National Cancer Institute NIH, 6701 Rockledge Drive, Room 5217, MSC 7840, Bethesda, MD 20892, USA
    Cancer Res 64:1460-7. 2004
    ..In addition, the chemical linkage and the considerations in therapeutic regimen described here could be applied to other immunoconjugates for targeted therapy of a broad spectrum of cancers...
  39. ncbi MR lymphangiography using dendrimer-based contrast agents: a comparison at 1.5T and 3.0T
    Yukihiro Hama
    Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1088, USA
    Magn Reson Med 57:431-6. 2007
    ..8+/-0.2 at 1.5T and 1.2+/-0.4 at 3.0T (P=0.003). Although 3D-FSPGR successfully delineated the LNs at both 1.5T and 3.0T, 3D-FIESTA-C at 3.0T failed to visualize the LNs...
  40. ncbi Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection
    Mikako Ogawa
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Bioconjug Chem 20:2177-84. 2009
    ..Multimodality molecular imaging combining activatable optical and radioactive probes has great potential for simultaneous visualization, characterization, and measurement of biological processes...
  41. ncbi Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Cancer Res 67:3809-17. 2007
    ..This two-step activation paradigm (pretargeting followed by neutravidin-biotin binding with an attached activatable fluorophore) could be useful in tumor-specific molecular imaging of various targets to guide surgical resections...
  42. ncbi Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore
    Andrew J Gunn
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bethesda, MD 20892 1088, USA
    Cancer Sci 98:1727-33. 2007
    ..These results indicate that galactosyl serum albumin-rhodamine green can selectively target a variety of human ovarian adenocarcinomas for optical fluorescence imaging and thus may improve intraoperative tumor detection and resection...
  43. ncbi Fluorescence lifetime imaging of activatable target specific molecular probes
    Raphael Alford
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1088, USA
    Contrast Media Mol Imaging 5:1-8. 2010
    ..In conclusion, fluorescence lifetime imaging monitors the internalization of target-specific activatable antibody-fluorophore conjugates in vitro. Challenges remain in adapting this methodology to in vivo imaging...
  44. ncbi Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer
    Nobuyuki Kosaka
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Cancer Sci 101:820-5. 2010
    ..Furthermore, serial-injection and mixed-injection strategies can modify antibody microdistribution within tumors and have the potential for preferential delivery of anticancer drugs to either the tumor periphery or its center...
  45. ncbi Galactosyl human serum albumin-NMP1 conjugate: a near infrared (NIR)-activatable fluorescence imaging agent to detect peritoneal ovarian cancer metastases
    Vinita M Alexander
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Bioconjug Chem 23:1671-9. 2012
    ..We conclude that hGSA-NMP1 is useful in imaging peritoneal ovarian cancer metastases, located both superficially and deep in the abdominal cavity...
  46. ncbi Activatable optical imaging with a silica-rhodamine based near infrared (SiR700) fluorophore: a comparison with cyanine based dyes
    Thomas E McCann
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1088, United States
    Bioconjug Chem 22:2531-8. 2011
    ..As a result, Av-SiR700 had higher TBRs compared to Av-Cy5.5 and better biostability compared to Av-Alexa Fluor 680...
  47. ncbi Imaging of tumor angiogenesis: functional or targeted?
    Baris Turkbey
    Molecular Imaging Program, National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm 1B40, Bethesda, MD 20892 1088, USA
    AJR Am J Roentgenol 193:304-13. 2009
    ..However, more quantitative methods based on functional and targeted imaging have recently emerged. CONCLUSION: In this article, we review both functional and targeted imaging techniques for assessing tumor angiogenesis...
  48. ncbi Near infrared fluorescence-guided real-time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green
    Nobuyuki Kosaka
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1088, USA
    Int J Cancer 129:1671-7. 2011
    ....
  49. ncbi H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging
    Mikako Ogawa
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1088, USA
    ACS Chem Biol 4:535-46. 2009
    ..Thus, H-dimer formation as a mechanism of fluorescence quenching could be used to develop fluorescence activatable probes for in vivo molecular imaging...
  50. ncbi In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies
    Mikako Ogawa
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room 1B40, MSC1088, Bethesda, MD 20892 1088, USA
    Mol Cancer Ther 8:232-9. 2009
    ....
  51. ncbi In vivo real-time, multicolor, quantum dot lymphatic imaging
    Nobuyuki Kosaka
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1088, USA
    J Invest Dermatol 129:2818-22. 2009
    ....
  52. ncbi Spectral near-infrared fluorescence imaging of curved surfaces using projection reconstruction algorithms
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1088, USA
    Contrast Media Mol Imaging 2:82-7. 2007
    ..Image stacking with subsequent application of appropriate projection techniques provides a simple method for deblurring in vivo optical images obtained from curved surfaces, thus improving their anatomic resolution...
  53. ncbi In vivo spectral fluorescence imaging of submillimeter peritoneal cancer implants using a lectin-targeted optical agent
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1088, USA
    Neoplasia 8:607-12. 2006
    ..These results suggest that targeted molecular imaging with a fluorescence-labeled lectin-ligand system is a promising technique for the detection of disseminated submillimeter foci of cancer...
  54. ncbi Targeted optical imaging of cancer cells using lectin-binding BODIPY conjugated avidin
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-1088, USA
    Biochem Biophys Res Commun 348:807-13. 2006
    ..These results suggest the lectin-targeted molecular imaging technique using a targeted green fluorescence probe is potentially useful in a wide variety of cancers with a proclivity for dissemination in the peritoneal space...
  55. ncbi In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green
    Mikako Ogawa
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute NIH, Bethesda, Maryland 20892 1088, USA
    Cancer Res 69:1268-72. 2009
    ..Because both the antibody and the fluorophore are Food and Drug Administration approved, the likelihood of clinical translation is improved...
  56. ncbi Tumor-specific detection of an optically targeted antibody combined with a quencher-conjugated neutravidin "quencher-chaser": a dual "quench and chase" strategy to improve target to nontarget ratios for molecular imaging of cancer
    Mikako Ogawa
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 1088, USA
    Bioconjug Chem 20:147-54. 2009
    ....
  57. ncbi Self-illuminating in vivo lymphatic imaging using a bioluminescence resonance energy transfer quantum dot nano-particle
    Nobuyuki Kosaka
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1088, USA
    Contrast Media Mol Imaging 6:55-9. 2011
    ..These advantages of BRET-QDot allowed us to perform real-time, quantitative lymphatic imaging without image processing. BRET-Qdots have the potential to be a robust nano-material platform for developing optical molecular imaging probes...
  58. ncbi Dendrimer-enhanced MRI as a diagnostic and prognostic biomarker of sepsis-induced acute renal failure in aged mice
    James W Dear
    Renal Diagnostics and Therapeutics Unit, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Kidney Int 67:2159-67. 2005
    ..CONCLUSION: Dendrimer-enhanced MRI is a novel biomarker that provides information for the early diagnosis, drug responsiveness, and prognosis of sepsis-induced ARF...
  59. ncbi New nanosized biocompatible MR contrast agents based on lysine-dendri-graft macromolecules
    Mikako Ogawa
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Research Technology Program, SAIC Frederick, Inc, NCI Frederick, USA
    Bioconjug Chem 21:955-60. 2010
    ....
  60. ncbi Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate
    Takahito Nakajima
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda Maryland 20892, United States
    Bioconjug Chem 22:1700-5. 2011
    ..25 mg/kg) of the reagent. This agent demonstrates promise as a method to image the extent of prostate cancer in vivo and could assist with real-time resection of extracapsular extension of tumor and positive lymph nodes...
  61. ncbi MR and optical imaging of early micrometastases in lymph nodes: triple labeling with nano-sized agents yielding distinct signals
    Nobuyuki Kosaka
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1088, USA
    Contrast Media Mol Imaging 7:247-53. 2012
    ..This platform offers a versatile research tool for investigating and treating lymphatic metastases in animal models...
  62. ncbi Multi-targeted multi-color in vivo optical imaging in a model of disseminated peritoneal ovarian cancer
    Nobuyuki Kosaka
    National Institutes of Health, National Cancer Institute, Center for Cancer Research, Molecular Imaging Program, 10 Center Drive, Bethesda, Maryland 20892 1088, USA
    J Biomed Opt 14:014023. 2009
    ..In conclusion, multitargeted multicolor optical imaging enabled specific in vivo diagnosis of tumors expressing distinct patterns of receptors, leading to improved diagnostic accuracy...
  63. ncbi In vivo stable tumor-specific painting in various colors using dehalogenase-based protein-tag fluorescent ligands
    Nobuyuki Kosaka
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bldg 10, Room 1B40, MSC 1088, 10 Center Drive, Bethesda, Maryland 20892 1088, USA
    Bioconjug Chem 20:1367-74. 2009
    ..Thus, this strategy can overcome some of the limitations associated with the use of endogenous fluorescent proteins and exogenous targeted optical agents in current use...
  64. ncbi Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance
    Hisataka Kobayashi
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 105:721-7. 2005
    ..Furthermore, our observation provides the scientific basis for a novel strategy to prevent cancer development/metastasis...
  65. ncbi Optimizing quantitative in vivo fluorescence imaging with near-infrared quantum dots
    Lauren T Rosenblum
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1088, USA
    Contrast Media Mol Imaging 6:148-52. 2011
    ..As a result, while wavelengths can be adjusted for qualitative experiments, the longest possible wavelengths should be used if quantification is desired during QD imaging experiments...
  66. ncbi Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity
    Yukihiro Hama
    Molecular Imaging Program, Center for Cancer for Cancer Research, National Cancer Institute, NIH, Bldg 10, Room 1B40, MSC 1088, Bethesda, MD 20892 1088, USA
    Breast Cancer Res Treat 103:23-8. 2007
    ....
  67. ncbi Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents
    Insook Kim
    Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1180, USA
    Nucl Med Biol 29:795-801. 2002
    ..The reduced renal uptake was also reflected in the reduced whole-body retention, indicating that lowering the pI inhibited the tubular reabsorption of the labeled dsFv...
  68. ncbi Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications
    Meyoung-Kon Kim
    Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, Bethesda, Maryland 20892, USA
    Nucl Med Biol 29:139-46. 2002
    ..3% ID/g for 99mTc-MAG3-Fab, whereas the glycolation resulted in a drastic reduction of the renal uptake at 15 min. We demonstrated that the renal clearance and the tumor targeting of Fab could be optimized by chemical modifications...
  69. ncbi Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates
    Raya Mandler
    Metabolism Branch, National Cancer Institute, NIH, Bethesda, Maryland 20982-1002, USA
    Bioconjug Chem 13:786-91. 2002
    ..However, unlike H:ABA-GA, the immunoconjugate H:APA-GA caused stable tumor regression (in 25% of the recipients), showing a qualitative improvement with potential clinical relevance...
  70. ncbi In vivo longitudinal imaging of experimental human papillomavirus infection in mice with a multicolor fluorescence mini-endoscopy system
    Makoto Mitsunaga
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Cancer Prev Res (Phila) 4:767-73. 2011
    ..This method offers the ability to monitor experimental virus infections before and after intervention, thereby accelerating the development of appropriate prevention and therapy...
  71. ncbi Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats
    Michelle Longmire
    Molecular Imaging Program, NCI NIH Building 10, Bethesda, MD 20892 1088, USA
    Nanomedicine (Lond) 3:703-17. 2008
    ....
  72. ncbi Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging
    Vladimir S Talanov
    Radiation Oncology Branch, Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1002, USA
    Nano Lett 6:1459-63. 2006
    ..The potential of the new nanoprobe, G6-(Cy5.5)(1.25)(1B4M-Gd)(145), as a dual modality imaging agent was demonstrated in vivo by the efficient visualization of sentinel lymph nodes in mice by both MRI and fluorescence imaging modalities...
  73. ncbi Imaging of the lymphatic system: new horizons
    Tristan Barrett
    Molecular Imaging Program, National Cancer Institute, Building 10, Room 1B40, Bethesda, MD 20892-1088, USA
    Contrast Media Mol Imaging 1:230-45. 2006
    ..The field of lymphatic imaging is ever evolving, and technological advances, combined with the development of new contrast agents, continue to improve diagnostic accuracy...
  74. ncbi Real-time optical imaging using quantum dot and related nanocrystals
    Nobuyuki Kosaka
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892 1088, USA
    Nanomedicine (Lond) 5:765-76. 2010
    ..Although toxicity and biodistribution of quantum dots and their close relatives remain prime concerns for translation to human imaging, these agents have many desirable features that should be explored for medical purposes...
  75. ncbi Molecular probes for the in vivo imaging of cancer
    Raphael Alford
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room 1B40, MSC1088, Bethesda, Maryland, MD 20892 1088, USA
    Mol Biosyst 5:1279-91. 2009
    ..Herein, we discuss advances in these imaging techniques, and focus on the major design strategies with which molecular probes are being developed...
  76. ncbi Clinical implications of near-infrared fluorescence imaging in cancer
    Nobuyuki Kosaka
    Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 1088, USA
    Future Oncol 5:1501-11. 2009
    ..NIR fluorescence imaging can compensate some limitations of conventional imaging modalities, and thus it could play an important role for cancer imaging combined with other modalities in clinical practice...
  77. ncbi Macromolecular MRI contrast agents for imaging tumor angiogenesis
    Tristan Barrett
    Molecular Imaging Program and Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, Building 10, Room 1B40, Bethesda, MD 20892-1088, USA
    Eur J Radiol 60:353-66. 2006
    ..Future applications of MMCM include targeted angiogenesis imaging and drug delivery of anti-cancer 'payloads'. Herein we discuss the best known MMCMs along with their advantages and disadvantages...
  78. ncbi Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent
    Hisataka Kobayashi
    Department of Diagnostic and Interventional Imagiology, Kyoto University, Kyoto, Japan. nih.gov
    Kidney Int 61:1980-5. 2002
    ..CONCLUSION: Contrast-enhanced, dynamic high-resolution micro-MRI with a novel dendrimer-based macromolecular renal MR contrast agent can be a powerful tool for in vivo observation of renal structural and functional damage...
  79. ncbi Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256)
    Hisataka Kobayashi
    Chaired Department of Diagnostic and Interventional Imagiology, Hitachi Medical Co, Kyoto 606-8507, Japan
    Cancer Res 62:860-6. 2002
    ....
  80. ncbi Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation
    Takayoshi Ishimori
    Department of Nuclear Medicine and Diagnostic Imaging, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Nucl Med 43:658-63. 2002
    ..The approach chosen was to examine the effect on (18)F-FDG uptake of acute activation of murine lymphocytes by concanavalin A (Con A)...
  81. ncbi Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model
    Kazuo Shirakawa
    Department of Surgery, Kawagoe Medical Center, Saitama Medical School, Saitama, Japan
    Breast Cancer Res 5:136-9. 2003
    ....
  82. ncbi Dynamic micro-MRI of liver micrometastasis with a novel liver macromolecular MR contrast agent DAB-Am64-(1B4M-Gd)64
    Hisataka Kobayashi
    Department of Diagnostic and Interventional Imagiology, Hitachi Medical Corporation, Tokyo, Japan
    Acad Radiol 9:S452-4. 2002
  83. ncbi Differential uptake of (18)F-fluorodeoxyglucose by experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of immunomodification
    Marcelo Mamede
    Department of Nuclear Medicine and Diagnostic Imaging, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan
    Neoplasia 5:179-83. 2003
    ....
  84. ncbi [In-vivo cancer fluorescence imaging with novel precisely-designed fluorescence probes]
    Yasuteru Urano
    Tanpakushitsu Kakusan Koso 52:1594-600. 2007
  85. ncbi Multiplexing with multispectral imaging: from mice to microscopy
    Richard M Levenson
    CRI Inc, Woburn, MA 01801, USA
    ILAR J 49:78-88. 2008
    ..Due to the same advantages in sensitivity, quantitation, and multiplexing, microscopy-based multispectral techniques form an excellent complement to in vivo imaging...
  86. ncbi Imaging acute renal failure with polyamine dendrimer-based MRI contrast agents
    James W Dear
    Renal Diagnostics and Therapeutics Unit, NIDDK, Bethesda, MD 20892-1268, USA
    Nephron Clin Pract 103:c45-9. 2006
    ..As an ARF biomarker, MRI with dendrimer-based contrast is a promising technique deserving further development...
  87. ncbi Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft
    Kazuo Shirakawa
    Pharmacology Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan
    Cancer Res 62:560-6. 2002
    ..These facts led us to hypothesize that the VM of WIBC-9 involves hemodynamics that serve to feed WIBC-9 cells, and this in turn suggests a connection between VM and angiogenesis...
  88. ncbi Radiolabeling of avidin with very high specific activity for internal radiation therapy of intraperitoneally disseminated tumors
    Marcelo Mamede
    Department of Nuclear Medicine and Diagnostic Imaging, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
    Clin Cancer Res 9:3756-62. 2003
    ..p. tumors, appears to be suitable for the internal radiation therapy of i.p. disseminated tumors using metallic radionuclides emitting Auger and conversion electrons...
  89. ncbi Hepatocyte targeting of 111In-labeled oligo-DNA with avidin or avidin-dendrimer complex
    Marcelo Mamede
    Department of Nuclear Medicine and Diagnostic Imaging, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
    J Control Release 95:133-41. 2004
    ..111In-oligo-bt-Av, which exhibited the highest hepatic uptake in vivo, also showed high and rapid internalization into hepatocytes. The avidin-biotin system seems to have potential as a carrier of oligo-DNA to the liver...
  90. ncbi Detection of inflammation following renal ischemia by magnetic resonance imaging
    Sang-Kyung Jo
    Renal Diagnostics and Therapeutics Unit, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Kidney Int 64:43-51. 2003
    ..This method might be useful to understand the pathogenesis of human ARF and to evaluate the effectiveness of anti-inflammatory agents...
  91. ncbi An enzymatically activated fluorescence probe for targeted tumor imaging
    Mako Kamiya
    Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 0033, Japan
    J Am Chem Soc 129:3918-29. 2007
    ..This strategy has potential clinical application, for example, in video-assisted laparoscopic tumor resection...
  92. ncbi Posterior cul-de-sac obliteration associated with endometriosis: MR imaging evaluation
    Milliam L Kataoka
    Department of Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Radiology 234:815-23. 2005
    ..To retrospectively evaluate the accuracy of magnetic resonance (MR) imaging in depicting posterior cul-de-sac obliteration in patients with endometriosis...
  93. ncbi Tumor-targeted optical imaging in the management of peritoneal carcinomatosis
    Andrew J Gunn
    Sanford School of Medicine, The University of South Dakota, USA
    S D Med 60:353-7. 2007
    ..This review discusses the current clinical management of peritoneal carcinomatosis as well as recent advances in the development of tumor-targeted optical fluorophores that may play a role in improving patient survival...
  94. ncbi Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry
    Heng Xu
    Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892 1088, USA
    J Med Chem 50:3185-93. 2007
    ..The latter aspect is further demonstrated by preparation of a novel maleimide analog of 1B4M-DTPA from a key synthetic intermediate aniline derivative...
  95. ncbi Lymphatic dysfunction in transgenic mice expressing KSHV k-cyclin under the control of the VEGFR-3 promoter
    Makoto Sugaya
    Dermatology Branch, National Cancer Institute, Office of Research Services, Division of Veterinary Resources, Bethesda, MD, USA
    Blood 105:2356-63. 2005
    ..kCYC may contribute to the development of certain clinical and histologic features of KS, including localized edema and retention of extravasated erythrocytes within KS tumors...
  96. ncbi Small numbers of residual tumor cells at the site of primary inoculation are critical for anti-tumor immunity following challenge at a secondary location
    Takashi Kakinuma
    Dermatology Branch, Center for Cancer Research, NCI, Bldg 10 Rm12N246, 10 Center Dr, Bethesda, MD 20892 1908, USA
    Cancer Immunol Immunother 56:1119-31. 2007
    ..These studies suggest that small numbers of tumor cells (possibly regulated by CD4(+)CD25(+) regulatory T cells expressing Foxp3) are required for effective host anti-tumor responses at alternate inoculation sites...